Asthma treatment using leukotriene receptor antagonist (LTRA) may not increase the risk of neuropsychiatric disease as feared in general after a US FDA warning. A study conducted by Ji-Su Shim, MD, of Ewha Womans University, Seoul, South Korea, and colleagues, reportedly did not find the hazard ratio for newly diagnosed neuropsychiatric diseases significantly different between LTRA users and nonusers. The FDA issued warnings against LTRAs, including a black box warning for montelukast (Singulair), of the risk for neuropsychiatric (NP) drug reactions. However,  the study results, published in the Journal of Allergy and Clinical Immunology: In Practice, pointed out that the analysis in 61,571 adult patients with asthma aged 40 years and older between January 2002 and December 2015, after dividing them into various groups of LTRA medication and others, found the hazard ratio for newly diagnosed neuropsychiatric diseases not significantly different between LTRA users and nonusers.